Compare ResMed Inc. (RMD) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? ResMed Inc. trades at $239.47 (market cap $33.09B), while SS&C Technologies Holdings Inc. Common Stock trades at $82.5 (market cap $19.25B). The key difference: ResMed Inc. is the larger of the two by market cap, and SS&C Technologies Holdings Inc. Common Stock pays the higher dividend (1.46%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| RMD | SSNC | |
|---|---|---|
Market Cap | $33.09B | $19.25B |
Volume | 1,019,685 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $275.96 | $89.62 |
52-Week Low | $182.82 | $62.05 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.45B | $26.59B |
Dividend Yield | 1.12% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $240.56, up 2.35% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $5.15B, net income of $1.40B (27.21% margin), and consistent earnings beats. Recent news highlights management's participation in healthcare conferences and upcoming Q1 2027 earnings on October 29, 2026.
Outlook remains positive with 12-14% EPS growth guidance and analyst consensus target of $243.56. Key risks include competitive pressures and ongoing legal investigations. Institutional ownership trends show continued accumulation by major funds, supporting the bullish sentiment.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
